Non-HA Vascular Occlusion Protocols

🚨 IN AN EMERGENCY? CLICK HERE FOR THE QUICK-ACTION CHEAT SHEET

Looking for the HA Filler Protocol? Read the Full HA Guidelines Here

Management of Non-HA Filler Vascular Occlusions (Biostimulators)

CRITICAL CONCEPT: THE ROLE OF HYALURONIDASE No true reversal agent exists to dissolve non-HA fillers like Calcium Hydroxylapatite (CaHA/Radiesse) or Poly-L-Lactic Acid (PLLA/Sculptra). However, hyaluronidase remains the cornerstone of acute management.

Mechanism of Action: Rather than dissolving the material, high-dose hyaluronidase relieves injection-induced arterial spasm and perforasome vasoconstriction. Ultrasound-guided hyaluronidase has successfully resolved CaHA and PLLA vascular occlusions without necrosis or scarring.

1. Universal Emergency Protocol (All Non-HA Fillers)

The immediate acute treatment protocol is identical to HA filler management:

High-Dose Pulsed Hyaluronidase: 1500 IU every 15-20 minutes injected into and around the affected area (use ultrasound guidance to target the vascular spasm).
Aspirin: 325 mg orally for antiplatelet effect.
Warm Compresses: Apply continuously to promote vasodilation.
Vigorous Massage: Mechanically disperse the product and stimulate blood flow.
Corticosteroids: Administer to control the inflammatory response.
Hyperbaric Oxygen Therapy (HBOT): 2 atmospheres absolute for 60 minutes as highly recommended adjunctive therapy.

2. Filler-Specific Complications & Management

Poly-L-Lactic Acid (PLLA / Sculptra)

Vascular Occlusion: Treat immediately with the Universal Protocol above. Cases of visual loss from periorbital/nasal and temple injections have been reported.
Nodules/Papules: The most common adverse event. Typically palpable but nonvisible, arising several weeks post-injection. Treatment: Vigorous massage, HA camouflage for visible nodules, intralesional corticosteroids, or 5-fluorouracil (5-FU) for persistent cases.
Granulomas: True inflammatory granulomas are rare (0.01%-0.1%), appearing months/years post-injection. Treat with corticosteroids and 5-FU.
Prevention: Allow adequate hydration/reconstitution time and strictly avoid superficial placement.

Calcium Hydroxylapatite (CaHA / Radiesse)

Vascular Occlusion: Treat immediately with the Universal Protocol. At least 11 published cases of visual impairment exist, most involving the nasal dorsum.
Nodules/Focal Accumulations: Follow this structured algorithmic approach:
- Level 0: Observation for asymptomatic nodules (degrades over 12-18 months).
- Level 1: Mechanical dispersion (vigorous massage or in situ dispersion using a blunt cannula to mechanically break up material).
- Level 2: Intralesional 5-FU/corticosteroids, laser treatments.
- Level 3 (Last Resort): Manual removal using a grater-type microliposuction cannula under ultrasound guidance, or surgical excision.

CONTROVERSY: Sodium Thiosulfate (STS) for CaHA The evidence for STS is conflicting. While in vitro studies show it dissolves CaHA, cadaveric studies show it fails to dissolve intraarterial CaHA. STS lacks robust clinical evidence for filler complications and should be considered a Level 3 (last-resort) intervention for nodules only. It is NOT a first-line treatment for vascular occlusion. Avoid entirely in lips/oral mucosa.

Other Biostimulators

Polycaprolactone (PCL): Facial artery embolism has been reported. Treat with Universal Protocol.
PDLLA-CMC & PDLLA-HA Composites: Cases of visual loss and posterior ischemic optic neuropathy (PION) reported. These may have occult lesions; promptly administer small-volume, high-concentration, multipoint hyaluronidase injections at the site.

3. Key Differences from HA Management

Mechanism: You are treating the vasospasm, not dissolving the product.
Ultrasound Dependency: Precision is even more critical. You must target the perforasome vasoconstriction precisely.
Mechanical Intervention: Massage, in situ cannula dispersion, and physical extraction play a much larger role, particularly for non-acute nodules.
Prevention is Paramount: Because treatment options are limited, meticulous technique, proper reconstitution, and avoiding high-risk zones are non-negotiable.

4. Visual Loss Management for Biostimulators

Prognosis for vision loss from biostimulators is extremely poor. If visual symptoms occur:

Immediate hyaluronidase (1500 IU) at the injection site and along vascular pathways.
Aspirin 325 mg orally.
Ocular massage and anterior chamber paracentesis.
IV mannitol for intraocular pressure reduction.
IMMEDIATE ophthalmology consultation.
Consider intra-arterial hyaluronidase, HBOT, and high-dose corticosteroids.

5. Ultrasound Sonographic Signatures: Locating the Culprit

When treating a vascular occlusion, especially with non-HA fillers where you are targeting the perforasome vasospasm rather than dissolving the product, identifying the filler type and location on ultrasound is critical. Here is what to look for when scanning the ischemic tissue:

Filler Type	Sonographic Appearance (B-Mode Ultrasound)	Key Artifacts
Hyaluronic Acid (HA)	Anechoic (Black) to Hypoechoic: Appears as well-defined, dark fluid-like collections or pseudocysts. NASHA products may look like distinct "pebbles," while Vycross/cohesive products look like diffuse, dark bands.	Posterior acoustic enhancement (brighter area deep to the filler).
Calcium Hydroxylapatite (CaHA / Radiesse)	Hyperechoic (Bright White): Highly reflective, echogenic deposits.	Strong posterior acoustic shadowing (dark shadow beneath the deposit) or "comet-tail" artifact.
Poly-L-Lactic Acid (PLLA / Sculptra)	Hyperechoic (Bright White): Diffuse, diffuse "cloud-like" or "snowstorm" appearance. Because of its large dilution volume, it rarely forms distinct, localized cysts like HA.	Mild acoustic shadowing; often obscures underlying fascial planes.
Polycaprolactone (PCL)	Hyperechoic (White): Well-defined, bright deposits, similar to CaHA but often slightly less dense.	"Comet-tail" artifact (reverberation) is highly characteristic.

Filler Type

Sonographic Appearance (B-Mode Ultrasound)

Key Artifacts

Hyaluronic Acid (HA)

Anechoic (Black) to Hypoechoic: Appears as well-defined, dark fluid-like collections or pseudocysts. NASHA products may look like distinct "pebbles," while Vycross/cohesive products look like diffuse, dark bands.

Posterior acoustic enhancement (brighter area deep to the filler).

Calcium Hydroxylapatite (CaHA / Radiesse)

Hyperechoic (Bright White): Highly reflective, echogenic deposits.

Strong posterior acoustic shadowing (dark shadow beneath the deposit) or "comet-tail" artifact.

Poly-L-Lactic Acid (PLLA / Sculptra)

Hyperechoic (Bright White): Diffuse, diffuse "cloud-like" or "snowstorm" appearance. Because of its large dilution volume, it rarely forms distinct, localized cysts like HA.

Mild acoustic shadowing; often obscures underlying fascial planes.

Polycaprolactone (PCL)

Hyperechoic (White): Well-defined, bright deposits, similar to CaHA but often slightly less dense.

"Comet-tail" artifact (reverberation) is highly characteristic.

6. Diagnostic Differentiator: Non-Inflammatory Nodules vs. True Granulomas

When managing delayed complications from biostimulators (particularly PLLA and CaHA), practitioners frequently misdiagnose non-inflammatory nodules as true granulomas. Misdiagnosis leads to incorrect management. Use these criteria to distinguish between the two:

Non-Inflammatory Nodules (Technique-Driven)

Onset: Early (Days to weeks post-injection).
Etiology: Product aggregation due to superficial placement, inadequate reconstitution/hydration, or lack of post-procedure massage.
Clinical Presentation: Firm, palpable, typically painless, and skin-colored. No signs of active inflammation.
Ultrasound Finding: A distinct, localized collection of the product. No increased blood flow on color Doppler.
Primary Treatment: Vigorous massage, mechanical dispersion (cannula), normal saline/lidocaine dilution.

True Granulomas (Immune-Mediated)

Onset: Late (Months to years post-injection). Often triggered by a systemic infection, dental work, or COVID-19/vaccination.
Etiology: A foreign body Type IV hypersensitivity reaction or a low-grade biofilm infection.
Clinical Presentation: Red, swollen, tender, warm, and often rapidly enlarging. May be accompanied by systemic symptoms.
Ultrasound Finding: Poorly defined margins, surrounding tissue edema ("halo" sign), and increased vascularity (hyperemia) within and around the lesion on color Doppler.
Primary Treatment: Intralesional corticosteroids (e.g., Kenalog), 5-Fluorouracil (5-FU), oral antibiotics (if biofilm suspected), and immune modulation. Mechanical dispersion is strictly contraindicated.

References

Kadouch J, Schelke L, Groh O, Sokol V, Velthuis P. Intralesional Hyaluronidase Injection to Relieve Non-Hyaluronic Acid Filler-Induced Vascular Adverse Events. Int J Dermatol. 2024;63(9):1252-1255.
Young SM, Goh ASC, Jeyabal P, Ooi ASH. Visual Loss in Biostimulator Injectables: A Review of Incidence, Risk Factors, Etiology and Management Proposal. Aesthetic Plast Surg. 2026;50(5):1994-2005.
Loyal J, Hartman N, Fabi SG, Butterwick KJ, Goldman MP. Cutaneous Vascular Compromise and Resolution of Skin Barrier Breakdown After Dermal Filler Occlusion. Dermatol Surg. 2022;48(6):659-663.
Madero J, Salvador M, Kadouch J, Muñoz-Gonzalez C, Fakih-Gomez N. Role of Hyperbaric Oxygen in Filler-Induced Vascular Occlusion. Aesthetic Plast Surg. 2024;48(14):2713-2721.
Li Z, Liu C, Gu L, et al. Intraoral Lesions Following Nose and Nasolabial Fold Augmentation Using Hyaluronic Acid/Poly-L-Lactic Acid Fillers. J Craniofac Surg. 2025.
Vleggaar D, Fitzgerald R, Lorenc ZP. Understanding, Avoiding, and Treating Potential Adverse Events Following the Use of Injectable Poly-L-Lactic Acid. J Drugs Dermatol. 2014;13(4 Suppl):s35-9.
Dayan SH, Arkins JP, Mathison CC. Management of Impending Necrosis Associated With Soft Tissue Filler Injections. J Drugs Dermatol. 2011;10(9):1007-12.
McCarthy AD, van Loghem J, Martinez KA, Aguilera SB, Funt D. A Structured Approach for Treating Calcium Hydroxylapatite Focal Accumulations. Aesthet Surg J. 2024;44(8):869-879.
Cohen SR, Patton S, Wesson J, Tiryaki KT, Mora A. Radiesse Rescue: A Preliminary Study for a Simple and Effective Technique for the Removal of Calcium Hydroxyapatite-Based Fillers. Aesthet Surg J. 2023;43(3):365-369.
Robinson DM. In Vitro Analysis of the Degradation of Calcium Hydroxylapatite Dermal Filler. Dermatol Surg. 2018;44 Suppl 1:S5-S9.
Yankova M, Pavicic T, Frank K, et al. Intraarterial Degradation of Calcium Hydroxylapatite Using Sodium Thiosulfate - An in Vitro and Cadaveric Study. Aesthet Surg J. 2021;41(5):NP226-NP236.
Pavicic T. Calcium Hydroxylapatite Filler: An Overview of Safety and Tolerability. J Drugs Dermatol. 2013;12(9):996-1002.